Pfizer Revises Its Tender Offer Price for Pfizer Limited

This release is neither an offer to purchase nor a solicitation of an offer to
sell shares of Pfizer Limited.
MUMBAI, India--(Business Wire)--
Pfizer Investments Netherlands B.V., an indirect wholly-owned subsidiary of
Pfizer Inc, announced today an increase to its Offer Price to acquire a 33.77%
stake in Pfizer Limited from public shareholders to Rs. 830 per share, an
increase of 23.0% to the original offer price of Rs. 675 per share.

The revised offer is being made at a premium of 33.5% to the closing share price
of Rs. 621.55 of Pfizer Limited on April 9, 2009, on the NSE (equivalent premium
of 33.2% to the closing price of Rs. 623.00 on that date on the BSE), which was
the last trading day before the announcement of the Tender Offer. It will also
represent a premium of 50.2% over Pfizer Limited`s average share price during
the 30 days ending April 9, 2009, on the NSE (and a premium of 50.4% over the
average share price during the 30 days ending April 9, 2009, on the BSE) and a
premium of 78.5% over the requisite price determined in accordance with the SEBI
(Substantial Acquisition of Shares and Takeovers) Regulations, 1997 ("SEBI
Regulations, 1997").

This proposal represents the company`s only and final price revision to this
Offer, as June 25 is the last day on which the Offer Price can be revised as per
the SEBI Regulations, 1997.

DISCLOSURE NOTICE: The information contained in this release is as of June 25,
2009.Pfizer assumes no obligation to update any forward-looking statements
contained in this release as the result of new information or future events or
developments.

This release contains forward-looking information about a tender offer for
shares in Pfizer Limited that involve substantial risks and uncertainties. Such
risks and uncertainties may include, among other things, receipt of the
remaining required regulatory approvals for the offer and acceptance of the
offer by public shareholders of Pfizer Limited.

Pfizer Inc
Media:
Priya Chandramohan, +91.22.66932316
Priya.Chandramohan@Pfizer.com
or
Joan Campion, +1 212-733-2798
Joan.Campion@pfizer.com
or
Investors:
Suzanne Harnett, +1 212-733-8009
Suzanne.Harnett@Pfizer.com

Copyright Business Wire 2009